Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials
Highlights
- Tolebrutinib reduced the risk of sustained disability progression in nonrelapsing secondary progressive multiple sclerosis (SPMS) compared to placebo.
- In relapsing multiple sclerosis (RMS), tolebrutinib was not superior to teriflunomide in reducing annualized relapse rates.
- Safety signals for tolebrutinib include higher rates of serious adverse events and liver enzyme elevations, as well as increased minor bleeding.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.